TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PharmaTher Holdings Ltd ( (TSE:PHRM) ) has provided an announcement.
PharmaTher Holdings Ltd. has completed the sale of its Abbreviated New Drug Application for Ketamine Hydrochloride Injection USP, receiving an upfront cash payment and potential future milestone and profit-sharing payments. This move allows PharmaTher to concentrate on its long-acting injectable ketamine program, which aims to provide a more convenient and effective treatment option for neuropsychiatric disorders, potentially improving patient adherence and expanding market access.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders.
Average Trading Volume: 246,028
Technical Sentiment Signal: Sell
Current Market Cap: C$10.47M
For a thorough assessment of PHRM stock, go to TipRanks’ Stock Analysis page.